63results about How to "Good prospects for commercial development" patented technology

The invention discloses an egg yolk antibody for preventing novel goose astrovirus and a preparation method thereof. The egg yolk antibody contains a goose astrovirus strain resistance antibody; the preservation number of the goose astrovirus strain is CCTCC NO:V201808. The prepared egg yolk antibody is good in safety, and no any partial or whole adverse reaction is caused by the egg yolk antibody; infections caused by novel goose astrovirus can be effectively prevented and/or treated, and the good commercialization development prospect is achieved.

The invention provides an I-group 4-type aviadenovirus genetic engineering subunit vaccine and a preparation method thereof. According to the technical scheme, the preparation method comprises the following steps: cloning an encoding gene of fibrous protein C-terminal from an I-group 4-type aviadenovirus genome according to a PCR technology and performing sequence analysis; cloning the gene to an expression vector pET-32a, transforming escherichia coli, constructing engineering bacteria, and inducing the engineering bacteria by isopropyl-beta-D-thiogalactopyranoside to express the fibrous protein C-terminal; performing lysis on an engineering bacterial cell, performing centrifugal separation on an inclusion body of the engineering bacterial cell, dissolving urea and diluting for renaturation; preparing the vaccine according to the conventional preparation method of a mineral oil adjuvant inactivated vaccine. According to the I-group 4-type aviadenovirus genetic engineering subunit vaccine prepared by the method, the immune effect of the vaccine is evaluated by a serological method and an immunity challenge method, and the result indicates that the aviadenovirus inactivated vaccine prepared by the method can provide effective immunoprotection and has a good commercialized development prospect.

The invention aims at providing a porcine pseudorabies virus vaccine. The porcine pseudorabies virus vaccine comprises an antigen and a protective agent, wherein the antigen contains an attenuated virus strain which is prepared after deleting virulence genes by a porcine pseudorabies virus strain with the collection number of CGMCC No. 10266. The prepared vaccine can effectively prevent porcine pseudorabies; furthermore, because the porcine pseudorabies virus as the antigen is a gene-deleted strain, by continuous passage of horizontally transmitted infections in mouse bodies, no virulence reversion occurs, and the genetic stability is realized, thereby being in line with the standard of having no virulence reversion in the porcine pseudorabies virus deleted vaccine strain; and the prepared vaccine can provide effective immune protection, and has great commercialization development prospects.

The invention aims at providing a porcine pseudorabies virus vaccine. The porcine pseudorabies virus vaccine comprises an antigen and a protective agent, wherein the antigen contains an attenuated virus strain which is prepared after deleting virulence genes, namely TK, gE and gI, by a porcine pseudorabies virus strain with the collection number of CGMCC No. 10266. The prepared vaccine can effectively prevent porcine pseudorabies; furthermore, because the porcine pseudorabies virus as the antigen is a gene-deleted strain, by continuous passage of horizontally transmitted infections in mouse bodies, no virulence reversion occurs, and the genetic stability is realized, thereby being in line with the standard of having no virulence reversion in the porcine pseudorabies virus deleted vaccine strain; and the prepared vaccine can provide effective immune protection, and has great commercialization development prospects.

The invention provides a red organic electrophosphorescent material iridium metal complex with the structure represented by formula (1). In the formula (1), R is a hydrogen atom or a C1-C4 straight chain or alkoxy group. The red organic electrophosphorescent material iridium metal complex is prepared through the following steps: carrying out a Grignard reaction on an iridium metal complex to prepare a compound C, carrying out dehydration cyclization on the compound C to obtain a cyclomedtalating ligand, carrying out a polymerization reaction on the cyclomedtalating ligand and chromium trichloride hexahydrate in a 2-ethoxyethanol and water mixed solvent to obtain a chlorendic dimer, and carrying out a complex reaction on the chlorendic dimer and acetylacetone to obtain the red organic electrophosphorescent material iridium metal complex represented by formula (1). The above material has good energy transmission efficiency and appropriate red light emitting wavelength, and can be widely used to make red or white phosphorescent electroluminescent devices in order to reduce the power consumption of the devices, improve the performances of the devices and prolong the life of the devices.

The invention aims at providing a duck adenovirus type 2 inactivated vaccine, wherein an antigen is an inactivated GD strain virus; and the GD strain virus is preserved in China Center for Type Culture Collection in Wuhan University on June 5, 2016 with preservation number of CCTCC No: V201633. The duck adenovirus type 2 inactivated vaccine prepared by the invention is good in safety and free from any local and systemic adverse reactions caused by the vaccine. Based upon analysis on characters, safety test and efficacy test data in a preservation period test, various indexes are stable and effective; and a result of assessing an immune effect of the vaccine by virtue of a serological method and an immune attack method shows that the inactivated vaccine prepared by the invention can achieve effective immune protection on ducks, and the inactivated vaccine has a good commercial development prospect.

The invention provides a red organic electrophosphorescent material iridium metal complex with the structure represented by formula (1). In the formula (1), R is a hydrogen atom or a C1-C4 straight chain or alkoxy group. The red organic electrophosphorescent material iridium metal complex is prepared through the following steps: carrying out a Suzuki coupling reaction on an iridium metal complex to prepare a cyclomedtalating ligand, carrying out a polymerization reaction on the cyclomedtalating ligand and chromium trichloride hexahydrate in a 2-ethoxyethanol and water mixed solvent to obtain a chlorendic dimer, and carrying out a complex reaction on the chlorendic dimer and an auxiliary ligand acetylacetone to obtain the red organic electrophosphorescent material iridium metal complex represented by formula (1). The above material has good energy transmission efficiency and appropriate red light emitting wavelength, and can be widely used to make red or white phosphorescent electroluminescent devices in order to reduce the power consumption of the devices, improve the performances of the devices and prolong the life of the devices.

The invention provides a duck adenovirus 2 and DPV (Muscovy duck parvovirus) disease combined inactivated vaccine. Antigens are inactivated duck adenovirus 2 and DPV, wherein the preservation number of the DPV is CCTCC NO:V201812, and the preservation number of the duck adenovirus 2 is CCTCC No:V201633. The prepared duck adenovirus 2 and DPV disease combined inactivated vaccine is good in safety and any local and general side effects caused by the vaccine are prevented. The analysis for character, safety test and efficacy test data in retention period tests indicates that all indexes are stable and effective; the immune effect of the vaccine is evaluated with a serological method and an immune challenge method, a result shows that the combined inactivated vaccine can provide effective immune protection for ducks and has good commercialized development prospect.

The invention provides a red organic electrophosphorescent material iridium metal complex with the structure represented by formula (1). In the formula (1), R is a hydrogen atom or a C1-C4 straight chain or alkoxy group. The red organic electrophosphorescent material iridium metal complex is prepared through the following steps: carrying out a Suzuki coupling reaction on an iridium metal complex to prepare a cyclomedtalating ligand, carrying out a polymerization reaction on the cyclomedtalating ligand and chromium trichloride hexahydrate in a 2-ethoxyethanol and water mixed solvent to obtain a chlorendic dimer, and carrying out a complex reaction on the chlorendic dimer and the cyclomedtalating ligand to obtain the red organic electrophosphorescent material iridium metal complex represented by formula (1). The above material has good energy transmission efficiency and appropriate red light emitting wavelength, and can be widely used to make red or white phosphorescent electroluminescent devices in order to reduce the power consumption of the devices, improve the performances of the devices and prolong the life of the devices.

The invention provides a live avian encephalomylitis and henpox combined vaccine. The combined vaccine consists of an antigen and a protective agent, wherein the antigen comprises henpox virus and avian encephalomylitis virus with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.8505. The combined vaccine prepared by the invention can be used for preventing avian encephalomylitis and henpox at the same time to achieve the aim of preventing two viruses with one injection. Furthermore, The avian encephalomylitis virus screened by the invention is an attenuated virus, performs serial passage in an avian body through horizontal transmitted infection, does not have the phenomenon of virulence return, is stable in heredity, and accords with the standard of no virulence return of an avian encephalomylitis attenuated vaccine strain; the prepared vaccine can provide effective immune protection, and has good commercial development prospect.

The invention discloses a porcine rotavirus strain as well as an inactivated vaccine prepared from the porcine rotavirus strain and application of the porcine rotavirus strain, and firstly discloses a separated porcine A-type rotavirus RVA/Pig-tc/CHN/SCMY-A3/2017/G9P [23] type strain (A3 strain for short), the microbial preservation number of the strain being V202132. The invention also discloses a preparation method of the porcine rotavirus inactivated vaccine, which comprises the following steps: mixing the virus liquid containing the A3 strain with the inactivating agent, inactivating the strain, and mixing the strain with the adjuvant to obtain the porcine rotavirus inactivated vaccine. The inactivated vaccine prepared from the separated porcine rotavirus can generate a higher antibody level and can resist the attack of virus strains.

The invention provides a red organic electrophosphorescent material iridium metal complex with the structure represented by formula (1). In the formula (1), each of R1 and R2 is a methyl group. The red organic electrophosphorescent material iridium metal complex is prepared through the following steps: carrying out a Suzuki coupling reaction on an iridium metal complex to prepare a cyclomedtalating ligand, carrying out a polymerization reaction on the cyclomedtalating ligand and chromium trichloride hexahydrate in a 2-ethoxyethanol and water mixed solvent to obtain a chlorendic dimer, and carrying out a complex reaction on the chlorendic dimer and an auxiliary ligand acetylacetone to obtain the red organic electrophosphorescent material iridium metal complex represented by formula (1). The above material has good energy transmission efficiency and appropriate red light emitting wavelength, and can be widely used to make red or white phosphorescent electroluminescent devices in order to reduce the power consumption of the devices, improve the performances of the devices and prolong the life of the devices.

The invention provides a red organic electrophosphorescent material iridium metal complex with the structure represented by formula (1). In the formula (1), each of R1 and R2 is a methyl group. The red organic electrophosphorescent material iridium metal complex is prepared through the following steps: carrying out a Grignard reaction on an iridium metal complex to prepare a compound C, carrying out dehydration cyclization on the compound C to obtain a cyclomedtalating ligand, carrying out a polymerization reaction on the cyclomedtalating ligand and chromium trichloride hexahydrate in a 2-ethoxyethanol and water mixed solvent to obtain a chlorendic dimer, and carrying out a complex reaction on the chlorendic dimer and acetylacetone to obtain the red organic electrophosphorescent material iridium metal complex represented by formula (1). The above material has good energy transmission efficiency and appropriate red light emitting wavelength, and can be widely used to make red or white phosphorescent electroluminescent devices in order to reduce the power consumption of the devices, improve the performances of the devices and prolong the life of the devices.